Amylyx Pharmaceuticals Inc (AMLX)
2.005
+0.08
(+3.89%)
USD |
NASDAQ |
May 02, 16:00
2.005
0.00 (0.00%)
After-Hours: 17:25
Amylyx Pharmaceuticals Enterprise Value: -240.54M for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 01, 2024 | -240.54M |
| April 30, 2024 | -248.68M |
| April 29, 2024 | -242.58M |
| April 26, 2024 | -252.07M |
| April 25, 2024 | -250.71M |
| April 24, 2024 | -243.93M |
| April 23, 2024 | -239.19M |
| April 22, 2024 | -237.15M |
| April 19, 2024 | -244.61M |
| April 18, 2024 | -237.15M |
| April 17, 2024 | -235.80M |
| April 16, 2024 | -235.12M |
| April 15, 2024 | -231.05M |
| April 12, 2024 | -229.02M |
| April 11, 2024 | -216.14M |
| April 10, 2024 | -204.62M |
| April 09, 2024 | -190.38M |
| April 08, 2024 | -189.03M |
| April 05, 2024 | -193.77M |
| April 04, 2024 | -194.45M |
| April 03, 2024 | -193.10M |
| April 02, 2024 | -193.77M |
| April 01, 2024 | -187.67M |
| March 28, 2024 | -178.86M |
| March 27, 2024 | -176.15M |
| Date | Value |
|---|---|
| March 26, 2024 | -185.64M |
| March 25, 2024 | -187.67M |
| March 22, 2024 | -185.64M |
| March 21, 2024 | -176.83M |
| March 20, 2024 | -170.05M |
| March 19, 2024 | -172.76M |
| March 18, 2024 | -177.51M |
| March 15, 2024 | -151.75M |
| March 14, 2024 | -156.49M |
| March 13, 2024 | -138.19M |
| March 12, 2024 | -138.19M |
| March 11, 2024 | -113.79M |
| March 08, 2024 | -143.61M |
| March 07, 2024 | 914.46M |
| March 06, 2024 | 919.89M |
| March 05, 2024 | 906.33M |
| March 04, 2024 | 925.99M |
| March 01, 2024 | 896.84M |
| February 29, 2024 | 906.33M |
| February 28, 2024 | 955.13M |
| February 27, 2024 | 916.50M |
| February 26, 2024 | 818.89M |
| February 23, 2024 | 824.99M |
| February 22, 2024 | 885.32M |
| February 21, 2024 | 666.38M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-252.07M
Minimum
Apr 26 2024
2.439B
Maximum
Dec 01 2022
1.129B
Average
1.101B
Median
Enterprise Value Benchmarks
| Cassava Sciences Inc | 835.87M |
| iRhythm Technologies Inc | 3.363B |
| Bristol-Myers Squibb Co | 135.68B |
| Moderna Inc | 34.07B |
| ACADIA Pharmaceuticals Inc | 2.369B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 4.731M |
| Revenue (Quarterly) | 108.45M |
| Total Expenses (Quarterly) | 106.52M |
| EPS Diluted (Quarterly) | 0.07 |
| Gross Profit Margin (Quarterly) | 91.37% |
| Profit Margin (Quarterly) | 4.36% |
| Earnings Yield | 34.91% |
| Operating Earnings Yield | 27.62% |
| Normalized Earnings Yield | 34.91 |